Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Summary

This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start

2004-10

Primary completion

2007-06

Completion

—

Drugs

Indications